Evercore ISI Group Lowers Price Target for Agilent Technologies to $128.00

Evercore ISI Group has maintained an "In-Line" rating for Agilent Technologies but lowered its price target from $130.00 to $128.00, a -1.54% change. The analyst's decision reflects Agilent's evolution into a leading life science and diagnostic firm, with a broad customer base across various end markets. The average one-year price target for Agilent is $132.27, with a high estimate of $150.00 and a low estimate of $120.00, indicating an 11.44% upside from the current price.

Agilent Technologies (A) has seen its stock price target adjusted by Evercore ISI, with the price target lowered from $130.00 to $128.00, a -1.54% change. This adjustment reflects Agilent's strong performance in the third quarter of 2025, which saw a 10.1% year-over-year revenue growth and a 19.1% increase in net income. The company also raised its full-year revenue guidance to $6.91–$6.93 billion, demonstrating confidence in its continued momentum [2].

Evercore ISI maintains an "In-Line" rating for Agilent, acknowledging the company's transformation into a leading life science and diagnostic firm. The analyst's decision is based on Agilent's broad customer base and its strong performance across key segments, including Pharma and Chemicals & Advanced Materials [2]. The company's CEO, Padraig McDonnell, highlighted the Ignite operating model and new product adoption as key drivers of growth, projecting margin improvements in the fourth quarter and for the full year 2026 [2].

The average one-year price target for Agilent is $132.27, with a high estimate of $150.00 and a low estimate of $120.00. This indicates an 11.44% upside from the current price of $125.63. Despite the price target adjustment, Agilent's stock has seen significant gains, with a 6.45% month-to-date increase and a 3.31% gain during the most recent full trading week [2].

The stock's performance has been driven by strong earnings, with EPS climbing 21.6% to $1.18 in Q3 2025. The company's revenue breakdown shows growth across its core operating segments, with the Life Sciences and Diagnostics Markets Segment contributing $670 million, the Agilent CrossLab Segment bringing in $744 million, and the Applied Markets Segment generating $324 million [2].

Agilent's recent performance and guidance suggest a positive outlook for the remainder of the fiscal year. The company's focus on operational efficiency, new product adoption, and margin improvement positions it for long-term growth, despite short-term pressures from increased commercial investments and variable pay costs [2].

References:
[1] https://www.marketscreener.com/news/evercore-isi-adjusts-price-target-on-agilent-technologies-to-128-from-130-maintains-in-line-ratin-ce7c50dfdf8df62d
[2] https://www.ainvest.com/news/agilent-technologies-2025-q3-earnings-strong-performance-net-income-rises-19-1-2508/
[3] https://www.marketbeat.com/stocks/NYSE/A/forecast/